This #WorldCancerDay, we spotlight the potential of circulating tumour DNA (ctDNA) testing, a transformative next step in the precision oncology journey. By enabling earlier detection, more personalised treatment decisions, and improved monitoring through minimally invasive liquid biopsies, ctDNA testing could help reshape the future of cancer care. Download the white paper to discover more. https://bit.ly/4byyeWN
IQVIA
Hospitals and Health Care
Durham, North Carolina 2,512,505 followers
Accelerate innovation for a healthier world.
About us
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific progress, in an effort to advance healthcare. To learn more, visit www.iqvia.com.
- Website
-
https://www.iqvia.com/
External link for IQVIA
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Public Company
- Specialties
- Technology, Consulting, and Clinical Development
Locations
-
Primary
Get directions
2400 Ellis Rd
Durham, North Carolina 27703, US
Employees at IQVIA
Updates
-
Combination therapies in oncology hold huge potential for improving patient outcomes, yet reimbursement of combination therapy across the UK and EU remains varied and limited in many markets. In this article in Drug Target Review, Anastasia Stamoulou, Jennifer Gaultney and Saskia Alexander - van Dijk discuss the barriers to positive HTA outcomes and the need for a multistakeholder approach to the solution. Read their insights in full: https://bit.ly/4teGX6P
-
The latest instalment of our Nine for 2026 blog series continues to bring you IQVIA's perspectives on the most significant trend-breaking issues shaping the year ahead. This time we are investigating the business and competitive trends rewriting strategies and commercial models – from biosimilars to AI-enabled HCP empowerment. Dive into the trends reshaping 2026. https://bit.ly/4rsGSL4
-
IQVIA is hiring! We currently have 100+ consulting roles open across the globe. Explore the opportunities, and find your place with us: https://bit.ly/3M6mEYw #WeAreIQVIA
-
-
IQVIA’s Irene Brusini, Suyin Lee, Jacob Hollingsworth, Amanda Sees, Matt Hackenberg, Nadea Leavitt, in collaboration with HealthShare Exchange’s Harm Scherpbier MD MS and Breakthrough T1D’s Raquel López-Díez, PhD, evaluated the feasibility of deploying machine learning models to identify adult-onset type 1 diabetes misclassified as type 2 in real-world health information exchange (HIE) data. Key insights: • National model performed well on HIE data • Localized retraining improved precision for patient screening • Data inconsistencies across HIEs remain a challenge for scalability These findings offer practical lessons for ML deployment in clinical settings beyond diabetes. https://lnkd.in/ddHxC5uG
-
Big news! IQVIA has once again claimed the top spot on the Fortune® World’s Most Admired Companies™ list for our industry — five years running. If creating a healthier world inspires you, this is the place to be. Join us: jobs.iqvia.com #WeAreIQVIA #MostAdmiredCos
-
-
Cancer treatments may improve overall survival but often cause nausea, vomiting, pain, and other side effects that lead to weakness, fatigue, and reduced physical and social functioning. Donald Stull’s new article in JCO explores how this “causal cascade” highlights the need for models estimating direct and indirect impacts on quality of life. https://bit.ly/3Z2cxqO
-
-
What’s next in hematology R&D? Find our experts’ take on what was discussed at the ASH Annual Meeting regarding repurposed agents, novel mechanisms, next gen cell therapies, and trial strategies! Read the @pharmaphorum article below.
Momentum in hematology promises meaningful change for patients worldwide. What can we do to help make that promise a reality? In this pharmaphorum article, Michael Armstrong, James French and Sarah Kromrey share insights and operational imperatives from the 2025 ASH Annual Meeting, highlighting how scientific advances and thoughtful trial design can work together to move innovation forward in meaningful ways. Read the article here: https://bit.ly/4bJ6TBb #CART #CAGT #Biotech #Biopharma #Regulatory
-
-
While JCA harmonizes clinical evidence evaluation across Europe, the first wave of implementation has made one thing clear: JCA readiness should be embedded into every stage of asset development. In this white paper, IQVIA’s Anke van Engen, Max Schlueter, Edel Falla, Sian Tanner and Xenia Radu-Sitavu, PhD discuss how organizations that view JCA as a strategic platform to demonstrate both the value and patient relevance of their innovations can achieve success. https://lnkd.in/de52kzvU
-
You've got questions, we've got answers. Check out our candidate FAQs for insights into our hiring process: https://bit.ly/4t6KBj2 #WeAreIQVIA